LFG
VNDA icon

Larson Financial Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Larson Financial Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86 Sell
14
-14
-50% -$91 ﹤0.01% 3660
2026
Q1 		$193 Buy
28
+20
+250% +$154 ﹤0.01% 3454
2025
Q4 		$71 Hold
8
– – ﹤0.01% 3360
2025
Q3 		$40 Buy
+8
New +$37 ﹤0.01% 3366

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Larson Financial Group's VNDA Position: Q2 2026 in Review

Larson Financial Group reduced its Vanda Pharmaceuticals (VNDA) stake by 50% in Q2 2026, selling an estimated $91 and leaving 14 shares worth $86. The position accounts for ﹤0.01% of the portfolio, ranked #3660.

Larson Financial Group first reported a position in VNDA in Q3 2025 and has held it in 4 quarters since. The position peaked at $193 in Q1 2026. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Larson Financial Group held 14 shares of Vanda Pharmaceuticals worth $86 as of Q2 2026.
  • Larson Financial Group sold 14 Vanda Pharmaceuticals shares in Q2 2026, an estimated $91.
  • Vanda Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3660 holding.
  • Larson Financial Group first reported a position in Vanda Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Vanda Pharmaceuticals position peaked at $193 in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.